NCT06243185 2024-02-06
Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
Peking Union Medical College Hospital
Phase 2 Unknown
Clinical Trials
82 trialsNCT06241105 2024-02-05
Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02489006 2024-01-17
NEO
University Health Network, Toronto
Phase 2 Unknown
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT06161272 2023-12-07
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Guangxi Medical University
Phase 2 Unknown
NCT05272462 2023-10-05
Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
Loyola University
Phase 2 Unknown
NCT03363867 2023-08-07
BEACON
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT05979298 2023-08-07
Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer
CureLab Oncology
Phase 2 Unknown
NCT05585281 2023-07-28
A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05430906 2023-04-25
AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer
Hunan Cancer Hospital
Phase 2 Unknown
NCT05819060 2023-04-19
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
Fudan University
Phase 2 Unknown
NCT03410784 2023-03-24
MITO28MaNGOov4
National Cancer Institute, Naples
Phase 2 Unknown
NCT04091204 2023-03-24
MITO 31
National Cancer Institute, Naples
Phase 2 Unknown
NCT05233982 2023-03-24
MITO 35a
National Cancer Institute, Naples
Phase 2 Unknown
NCT03321188 2023-02-06
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Phase 2 Unknown
NCT05453825 2023-01-31
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
OncXerna Theraputics, Inc.
Phase 2 Unknown
NCT03430700 2023-01-30
PROMPT
University College, London
Phase 2 Unknown
NCT05669768 2023-01-03
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Sun Yat-sen University
Phase 2 Unknown
NCT02125513 2022-12-30
GOGER-01
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 2 Unknown
NCT05641506 2022-12-07
A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT05597527 2022-10-28
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04398446 2022-09-01
Coala-T-CBD
Main Line Health
Phase 2 Unknown
NCT02562365 2022-07-27
ACTS
Fudan University
Phase 2 Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT02033616 2022-04-25
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
Aivita Biomedical, Inc.
Phase 2 Unknown
NCT05342506 2022-04-22
Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05311579 2022-04-13
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05310344 2022-04-04
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05170594 2021-12-28
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Unknown
NCT04375956 2021-12-20
MITO 27
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT04217798 2021-09-01
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04887961 2021-08-09
MITO36
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT04734665 2021-07-12
NIRVANA-R
Yonsei University
Phase 2 Unknown
NCT04836663 2021-06-01
A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT00703105 2021-04-26
Ovarian Dendritic Cell Vaccine Trial
Loyola University
Phase 2 Unknown
NCT04828616 2021-04-02
Study of DP303c Injection in Patients With Advanced Ovarian Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT04815408 2021-03-25
PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04068974 2021-03-16
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04661696 2020-12-10
Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.
ChineseAMS
Phase 2 Unknown
NCT04566952 2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04590625 2020-10-19
Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
Zhongshan Hospital Xiamen University
Phase 2 Unknown
NCT03899610 2020-09-28
KGOG3046
Yonsei University
Phase 2 Unknown
NCT04383977 2020-05-12
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT03556566 2019-08-30
V3-OVA
Immunitor LLC
Phase 2 Unknown
NCT03942068 2019-05-08
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03924882 2019-04-23
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT03412526 2019-04-04
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian
Sheba Medical Center
Phase 2 Unknown
NCT03818282 2019-02-26
OC-01
Huazhong University of Science and Technology
Phase 2 Unknown
NCT03618706 2018-08-07
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer
Yonsei University
Phase 2 Unknown
NCT03547375 2018-06-06
Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy
Anhui Provincial Hospital
Phase 2 Unknown